Skip to main content

Table 2 Summary for results of PFGE fingerprint patterns and antibiotic susceptibility among clinical Acinetobacter baumannii isolates in the PFGE study

From: Tracing the emergence of multidrug-resistant Acinetobacter baumannii in a Taiwanese hospital by evaluating the presence of integron gene intI1

Number P11 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12
Isolates year 2001 2001 2002 2002 2003 2003 2004 2004 2001 2002 2003 2004
PFGE type A B C B A A B D A A E A
Carrying-Int I1 + + + + + + + + - - - -
AN R2 R R R R S R R R S R S
SAM R R R R R R R R R R R R
CTZ S S R S R S R S R S S R
LVF S S S S S S S S S S S S
IMP S S S S S S R S S S R S
PIP-TAZ S R S R S R S R S R S S
CRO S S R S R S R S R S S R
  1. Notes:
  2. 1P number is the Lane number of PFGE study.
  3. 2S: Susceptible; R: Resistant; I: Belonged to resistant.
  4. 3The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l'Etoile, France). The results were interpreted using the CLSI breakpoints (Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing).
  5. 4Abbreviation AN: amikacin; SAM: Ampicillin-sulbactam; CTZ: Ceftazidime; LVF: Levofloxacin; IMP: Imipenem-cilastatin; PIP-TAZ: Piperacillin-tazobactam; CRO: Ceftriaxone; colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.